DP
SPRY icon

Diadema Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Diadema Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-280,700
Closed -$4.9M – 164
2025
Q2 		$4.9M Buy
+280,700
New +$4.05M 1.49% 22
2025
Q1 		– Sell
-3,200
Closed -$33.8K – 148
2024
Q4 		$33.8K Buy
+3,200
New +$44.8K 0.01% 100

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Diadema Partners's SPRY Position: Q2 2026 in Review

Diadema Partners opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 4,860 shares worth $38.9K. The stake represents ﹤0.01% of the portfolio and ranks #140 among its holdings.

208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Diadema Partners held 4,860 shares of ARS Pharmaceuticals worth $38.9K as of Q2 2026.
  • ARS Pharmaceuticals was a new Diadema Partners position in Q2 2026.
  • ARS Pharmaceuticals made up ﹤0.01% of Diadema Partners's portfolio in Q2 2026, its #140 holding.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.